Review
Oncology
Inga Bekes, Jens Huober
Summary: Seventy percent of breast cancer subtypes are hormone receptor-positive, and adjuvant endocrine therapy is crucial for these patients. Extending adjuvant endocrine therapy beyond 5 years has been shown to reduce the risk of late recurrence, but the optimal duration is still debated. Newer data suggest only marginal benefits beyond 7 to 10 years, and longer duration may result in more side effects. Therefore, it is important to select patients who qualify for extended therapy based on genomic tests and risk assessment.
Article
Endocrinology & Metabolism
S. Bailey, G. Mhango, J. J. Lin
Summary: Bone mineral density screening prior to initiating aromatase inhibitor therapy reduces the risk of bone fractures and healthcare resource utilization among postmenopausal breast cancer survivors.
OSTEOPOROSIS INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Yoshimi Ouchi, Katsuhiko Nakatsukasa, Koichi Sakaguchi, Midori Morita, Hiroshi Koyama, Takayuki Matsuda, Makoto Kato, Eiichi Konishi, Hisako Ono, Tetsuya Taguchi
Summary: This study showed that twice-yearly administration of denosumab to breast cancer patients treated with adjuvant AI resulted in significant increases in bone mineral density at the lumbar spine, right femoral neck, and left femoral neck over a 36-month treatment period. There were no non-traumatic clinical fractures in patients receiving AI and denosumab treatment.
JOURNAL OF BONE AND MINERAL METABOLISM
(2021)
Article
Endocrinology & Metabolism
Taihu Wan, Yuhang Zhu, Qinghe Han, Lin Liu
Summary: The study found that spinal marrow fat content significantly increased in postmenopausal women with hormone-receptor-positive breast cancer receiving AI treatment over a 12-month period.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
S. A. Gooijer, C. Folkersma, J. E. C. van Steenhoven, J. de Kort, S. Siesling, J. Volders, T. van Dalen
Summary: This study investigated the efficacy of endocrine monotherapy (ET) in elderly breast cancer patients in terms of avoiding invasive local treatment. The results showed that for a select group of elderly patients, the risk of death was twice as high compared to the risk of undergoing invasive local treatment.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
S. A. Gooijer, C. Folkersma, J. E. C. van Steenhoven, J. de Kort, S. Siesling, J. Volders, T. van Dalen
Summary: For a select group of elderly breast cancer patients, endocrine therapy can be discussed as a safe and effective alternative to invasive local treatment, with a higher risk of dying than undergoing such treatment.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jooyoung Oh, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Jeong-Ho Seok, Woo-Chan Park, Jae-Jin Kim, Chang Ik Yoon
Summary: This study, using a nationwide population-based cohort, found no evidence that endocrine treatment increases the risk of depression in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Johanna E. Poterala, Kari B. Wisinski
Summary: A shorter course of endocrine therapy may be reasonable for breast cancer patients with low estrogen receptor expression, but further validation is needed.
Article
Oncology
Wei-Chung Shia, Li-Sheng Lin, Hwa-Koon Wu, Chih-Jung Chen, Dar-Ren Chen
Summary: This study evaluated the association between hormone therapy-induced mammographic density reduction and prognosis in breast cancer patients. It found that a mammographic density reduction rate >20.8% was a significant predictor of prognosis in these patients.
Article
Pharmacology & Pharmacy
Junmei Cairns, Krishna R. Kalari, James N. Ingle, Lois E. Shepherd, Matthew J. Ellis, Paul E. Goss, Poulami Barman, Erin E. Carlson, Barbara Goodnature, Matthew P. Goetz, Richard M. Weinshilboum, Huanyao Gao, Liewei Wang
Summary: Genetic factors were found to differentiate the efficacy of adjuvant anastrozole and exemestane in the treatment of breast cancer, but they did not show any association with treatment outcomes in the combined analysis. Studies suggested potential genetic biomarkers for selecting an aromatase inhibitor for individual patients based on SNPs near LY75 and GPR160 related to epithelial-to-mesenchymal transition and growth pathways.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Article
Multidisciplinary Sciences
Eun Heui Kim, Yun Kyung Jeon, Kyoungjune Pak, Taewoo Kang, Kyung-Eun Kim, Seong-Jang Kim, In-Joo Kim, Keunyoung Kim
Summary: This study compared the changes in lumbar spine and femur BMD and TBS in breast cancer patients undergoing TMXF or TMXF combined with GnRH analog therapy. TBS was found to be more sensitive in reflecting bone microarchitectural changes caused by hormone therapies compared to BMD.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jennifer D. Brooks, Rebecca A. G. Christensen, Janice S. Sung, Malcolm C. Pike, Irene Orlow, Jonine L. Bernstein, Elizabeth A. Morris
Summary: This study examined the relationship between BPE and MRI-FGT as well as breast cancer risk factors. The results showed a positive association between BMI and BPE, while BMI had an inverse relationship with MRI-FGT. Additionally, the use of preventive medication was associated with low BPE.
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)